Aardvark Therapeutics, Inc. (AARD) · Oct 23, 2026 · Other events
Clinical hold lifted — FDA hold lifted; HERO stopped early before planned enrollment
Aardvark’s FDA clinical hold is lifted for ARD-101, reopening the PWS program—but early-stopped HERO data offers only an exploratory efficacy signal.
Aardvark is a clinical-stage biotech building ARD-101 as an oral treatment for hyperphagia in Prader-Willi syndrome, with broader metabolic-disease ambitions. The company had been navigating a full FDA clinical hold after pausing its Phase 3 program over cardiac findings at high doses.
The regulatory block is cleared, but the pivotal program is not back on a normal track. The filing says the FDA lifted the clinical hold, which removes the immediate regulatory stop and keeps ARD-101’s development path open. 〔0〕 But the HERO and open-label studies were already terminated early, enrollment was truncated, and the filing explicitly says the results should be considered exploratory. 〔1〕 This is a meaningful recovery from the hold, not a clean clinical win.
The efficacy signal is encouraging in direction but too incomplete to establish proof. The company reports a modest reduction in hyperphagia scores versus placebo, faster improvement by Week 2, additional improvement when placebo patients switched to ARD-101, and rebound after treatment stopped. 〔2〕 Those patterns support a possible drug effect, but the early termination leaves limited Week 12 data and no properly powered final efficacy test.
| Measure | Filing result | Comparison / limitation |
|---|---|---|
| HERO randomized design | ARD-101 n=45; placebo n=45 planned | Trial stopped early; 67 participants enrolled overall (HERO design / Executive Summary) |
| Baseline HERO HQ-CT | ARD-101 22.5; placebo 22.8 | Roughly balanced starting severity (HERO Scores) |
| Cardiac safety | 3 of 31 high-dose healthy volunteers had QRS increases >25% | Findings were reversible; no QRS prolongation at 200 mg or 400 mg BID (Cardiac Safety) |
| HERO treatment-emergent AEs | 52% ARD-101; 50% placebo | Mostly mild to moderate (Safety Summary) |
| Serious cardiac event | One Grade 4 polymorphic ventricular tachycardia event | Occurred at 800 mg BID with concurrent pitolisant (Safety Summary) |
The safety story is improved at therapeutic exposures, but not erased. The follow-up studies found no QRS prolongation at the intended 200 mg BID dose or the 400 mg BID supratherapeutic dose, and no QTc increases in healthy volunteers. 〔3〕 That addresses the specific signal that triggered the hold, while the prior Grade 4 cardiac event and the CYP2D6 interaction with pitolisant remain important constraints for future trial design and patient selection.
Bottom line: Lifting the hold preserves ARD-101’s development option and removes the immediate regulatory overhang, but the truncated HERO dataset is not strong enough to validate efficacy. The story moves from “blocked” to “back in play, with a redesigned or additional clinical path still to prove.”
Webcast reviewing HERO/OLE data, October 23
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!